It is crucial to be aware of the risk factors and symptoms associated with AMD to detect and manage the condition early.

The DISCOVER Phase 1/2a trial is an open-label, single ascending dose, 9-month study that will evaluate the safety and bioactivity of AXT107 ...

Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible ...

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia GlobeNewswire May 06 ...

Mesogen Inc. out of The Woodlands, Texas, has developed a transplantable Retinal Pigmented Epithelium (RPE) patch to cure ...

Macular degeneration is a prevalent eye disorder that typically results in loss of vision in individuals who are 50 years of age and older. Although there isn’t a recognized cure for this ...

Boehringer Ingelheim has reported positive data from the HORNBILL Phase I/IIa clinical trial of the humanised monoclonal anti-Sema3A antibody, BI 764524, as a potential treatment for diabetic macular ...

A recent study found home-monitoring tests as a potential solution to reduce the burden of neovascular age-related macular ...

To provide opportunity for encouragement, Phoenix-based Associated Retina Consultants, in coordination with the International ...

Named PRIMA, the device may help those with advanced dry age-related macular degeneration get improvements in their eyesight. The company is in talks to also conduct trials in the United States.

The Macular Disease Foundation says consuming more than 12g of alcohol a day, which is less than one large glass of wine or a large beer, is linked to a larger risk of age-related macular ...

The Macular Disease Foundation says consuming more than 12g of alcohol a day, which is less than one large glass of wine or a ...